Department of Genetics, University of Córdoba, Córdoba, Spain.
J Med Food. 2011 Jul-Aug;14(7-8):681-7. doi: 10.1089/jmf.2010.0137. Epub 2011 May 25.
The "Spanish Ketogenic Mediterranean Diet" (SKMD) has been shown to promote potential therapeutic properties for the metabolic syndrome. The purpose of this study was to evaluate the potential therapeutic properties under free-living conditions of the SKMD in patients with metabolic syndrome (following the International Diabetes Federation consensus guidelines) over a 12-week period. A prospective study was carried out in 22 obese subjects with metabolic syndrome (12 men and 10 women) with the inclusion criteria whose body mass index of 36.58 ± 0.54 kg/m² and age was 41.18 ± 2.28 years. Statistical differences between the parameters studied before and after the administration of the SKMD (week 0 and 12, respectively) were analyzed by paired Student's t test. There was an extremely significant (P < .001) improvement in low-density lipoprotein cholesterol (from 126.25 mg/dL to 103.87 mg/dL) and all the parameters studied associated with metabolic syndrome: body weight (from 106.41 kg to 91.95 kg), body mass index (from 36.58 kg/m² to 31.69 kg/m²), waist circumference (from 111.97 cm to 94.70 cm), fasting plasma glucose (from 118.81 mg/dL to 91.86 mg/dL), triacylglycerols (from 224.86 mg/dL to 109.59 mg/dL), high-density lipoprotein cholesterol (from 44.44 to 57.95 mg/dL), systolic blood pressure (from 141.59 mm Hg to 123.64 mm Hg), and diastolic blood pressure (from 89.09 mm Hg to 76.36 mm Hg). The most affected parameter was the triacylglycerols (51.26% reduction). After the diet all the subjects were free of metabolic syndrome according to the International Diabetes Federation definition, and 100% of them had normal triacylglycerols and high-density lipoprotein cholesterol levels, in spite of the fact that 77.27% of them still had a body mass index of > 30 kg/m². We conclude that the SKMD could be an effective and safe way to cure patients suffering from metabolic syndrome. Future research should include a larger sample size, a longer-term use, and a comparison with other ketogenic diets.
“西班牙生酮地中海饮食”（SKMD）已被证明对代谢综合征具有潜在的治疗作用。本研究的目的是在 12 周的时间内，评估 SKMD 在代谢综合征患者（符合国际糖尿病联合会共识指南）的自由生活条件下的潜在治疗作用。对 22 名患有代谢综合征的肥胖患者（12 名男性和 10 名女性）进行了一项前瞻性研究，纳入标准为体重指数为 36.58±0.54kg/m²，年龄为 41.18±2.28 岁。通过配对学生 t 检验分析了 SKMD 给药前后（分别为第 0 周和第 12 周）研究参数之间的统计学差异。低密度脂蛋白胆固醇（从 126.25mg/dL 降至 103.87mg/dL）和所有与代谢综合征相关的参数均有显著改善（P<0.001）：体重（从 106.41kg 降至 91.95kg）、体重指数（从 36.58kg/m²降至 31.69kg/m²）、腰围（从 111.97cm 降至 94.70cm）、空腹血糖（从 118.81mg/dL 降至 91.86mg/dL）、三酰甘油（从 224.86mg/dL 降至 109.59mg/dL）、高密度脂蛋白胆固醇（从 44.44mg/dL 升至 57.95mg/dL）、收缩压（从 141.59mmHg 降至 123.64mmHg）和舒张压（从 89.09mmHg 降至 76.36mmHg）。受影响最大的参数是三酰甘油（降低 51.26%）。饮食结束后，所有患者均符合国际糖尿病联合会的定义，无代谢综合征，其中 100%的三酰甘油和高密度脂蛋白胆固醇水平正常，尽管其中 77.27%的患者体重指数仍>30kg/m²。我们得出结论，SKMD 可能是治疗代谢综合征患者的一种有效且安全的方法。未来的研究应包括更大的样本量、更长时间的使用以及与其他生酮饮食的比较。
